Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Palisade Bio (NASD

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Raccontata dabenzinga.com